We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
Program: AZP-531, unacylated ghrelin analog, for the treatment of the Prader-Willi syndrome and type 2 diabetes
Status: clinical Phase II - Unpartnered
Program: Pegcrisantaspase (Asparec®, JZP-416), PEgylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia
Status: clinical Phase I – Partnered (Jazz Pharmaceuticals)
To be announced soon